AUTHORS
Tereza Novakova, Daniel Bilek, MSc2, David Zihala3, Martin Stork, MD, PhD4, Vladimir Maisnar5, Luca Bertamini, MD6, Vojtech Latal, MD7, Lukas Stejskal, MD8, Marek Wrobel, MD9, Petr Kessler, MD10, Petr Pavlicek, MD11, Ullrychova Jana, MD12, Juliana Holasova13, Lubica Harvanova, MD14, Alexandra Jungova, MD, PhD15, Jakub Radocha, MD, PhD16, Ivan Špicka17, Jiri Minarik, MD, PhD18, Bruno Paiva, PhD19, Ludek Pour, MD20, Roman Hajek, MD, PhD21, Tomas Jelinek Sr, MD22
AFFILIATIONS
1 Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic, Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
2 Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic, Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic, Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
3 Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic, Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic, Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
4 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
5 4th Department of Internal Medicine – Hematology, Faculty of Medicine, Charles University and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
6 Department of Hematology, Erasmus MC Cancer Institute Rotterdam, Rotterdam, Netherlands
7 Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic
8 Silesian Hospital in Opava, Opava, Czech Republic
9 Hematology department, Hospital in Novy Jicin, Novy Jicin, Novy Jicin, Czech Republic
10 Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Pelhrimov, Pelhrimov, Czech Republic
11 Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
12 KZ, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Usti nad Labem, Czech Republic
13 Department of Hematology, University Hospital F. D. Rooosevelt, 97517 Banska Bystrica, Banska Bystrica, Slovakia
14 Department of Hematology and Transfusiology, Faculty of Medicine, Comenius University and Slovak Medical University, University Hospital Bratislava, Bratislava, Slovakia
15 From the Department of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic
16 4th Department of Internal Medicine – Hematology, Faculty of Medicine, Charles University and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
17 1st Department of Medicine—Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
18 Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic
19 Clinica Universidad de Navarra, Centro de Investigaciones Medicas Aplicadas (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
20 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
21 Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic, Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
22 Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic, Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
ABSTRACT
Background
Accurate risk assessment is essential in multiple myeloma (MM), yet the applicability of established staging systems can be limited, as cytogenetic data are unavailable in 20–30% of patients in trials. Circulating tumor cells (CTCs) have emerged as a promising blood-based prognostic biomarker in newly diagnosed MM (NDMM). The recently proposed CTC staging system (CTC-SS) integrates CTC counts with conventional blood-based clinical parameters and has shown prognostic performance comparable to R-ISS (Bertamini et al., 2026). However, the CTC-SS lacks independent validation, and its applicability in relapsed/refractory MM (RRMM) remains unknown.
Methods
We analyzed 895 NDMM and 389 RRMM patients with available CTC measurements treated between 2022 and 2026 and included in the Czech Registry of Monoclonal Gammopathies (RMG). CTCs were quantified using flow cytometry according to Czech national guidelines, with median limit of detection of 0.0008%. CTC-SS was calculated by summing points for CTC level (<0.002%, 0; 0.002–0.02%, 1; 0.02–0.2%, 2; 0.2–2%, 3; ≥2%, 6), ISS stage (I, 0; II, 1; III, 2), and LDH status (normal, 0; elevated, 2). Patients were classified as low- (0–1 points), intermediate- (2–4 points), or high-risk (≥5 points) groups. Progression-free survival (PFS) and overall survival (OS) according to CTC-SS and R-ISS were compared in both cohorts. The median follow-up was 15.9 and 17.5 months (mo) in the NDMM and RRMM cohorts, respectively. Model performance was assessed using Harrell's C-index and time dependent AUC at 6, 12, 18, 24, and 30 mo.
Results
CTC-SS and R-ISS were available for 877 (98.0%) and 695 (77.7%) patients in NDMM, and 308 (79.1%) and 267 (68.6%) samples in RRMM setting, respectively. R-ISS high-risk cytogenetics [t(14;16), t(4;14), and/or del17p] were unavailable in 272 (30.4%) NDMM and 104 (26.7%) RRMM patients. Analyses were restricted to patients with both systems available, and for RRMM, the first timepoint with available staging was selected, resulting in 693 NDMM and 230 RRMM patients.
In NDMM, CTC-SS and R-ISS classified 19.3% vs. 15.7% as stage I, 54.3% vs. 61.2% as stage II, and 26.4% vs. 23.1% as stage III. Median PFS was not reached (NR), 24.4, and 11.2 mo for CTC-SS stages I–III, respectively, while 30-month OS was 85.4%, 75.6%, and 62.5%. Corresponding R-ISS median PFS and 30-month OS were NR, 24.8, and 12.1 mo and 86.5%, 75.7%, and 60.0%, respectively. All pairwise comparisons of PFS and OS between stages were significantly different (BH adjusted p<0.01).
CTC-SS showed predictive performance comparable to R-ISS in NDMM. C-index was slightly higher for CTC-SS (0.634 vs. 0.617). Time-dependent AUC consistently favored CTC-SS across all time points (0.657 vs. 0.642, 0.669 vs. 0.653, 0.658 vs. 0.638, 0.646 vs. 0.613, and 0.652 vs. 0.615 at mo 6, 12, 18, 24, and 30, respectively).
In the RRMM cohort, the distribution of patients across the three risk groups differed between the two systems, with 36.5% versus 25.2% classified as stage I, 51.3% versus 60.4% as stage II, and 12.2% versus 14.3% as stage III for CTC-SS and R-ISS, respectively. Median PFS across CTC-SS stages I–III was 24.0, 14.5, and 3.2 mo, respectively, while median OS was NR, 26.9, and 4.6 mo. Median PFS according to R-ISS was 28.1, 11.8, and 4.1 mo, and median OS was 34.3, 27.7, and 8.9 mo, respectively. The OS estimate for R-ISS stage I should be interpreted with caution, as it was reached late in the follow-up period, resulting in a highly unstable survival estimate (95% CI: 0.2–1.0). All pairwise comparisons of PFS and OS between stages were significantly different (BH adjusted p<0.01), except for PFS of CTC-SS Stage I and II (p=0.06).
In RRMM, predictive performance was comparable, although temporal dynamics differed. C-index was slightly lower for CTC-SS (0.612 vs. 0.621). However, time-dependent AUC revealed that while R-ISS performed better during the first year of follow-up (0.624 vs. 0.652 at month 6, and 0.619 vs. 0.640 at month 12), CTC-SS outperformed it thereafter (0.644 vs. 0.622, 0.659 vs. 0.627, and 0.632 vs. 0.565 at mo 18, 24, and 30, respectively).
Conclusions
These findings provide a validation of minimally invasive CTC-SS in NDMM and establish, for the first time, its applicability in RRMM. With performance comparable to R-ISS, blood-based CTC-SS provides an accessible tool for risk stratification when genomic data are unavailable.
DISCLOSURES
Tereza Novakova: No relevant conflicts of interest to declare.